CAMBRIDGE, MA / ACCESS Newswire / November 19, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced the expansion of its U.S. manufacturing capabilities with the onshoring of Drug Product manufacturing ...
Moderna’s shares rallied after the biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial. In early trading, the shares were 4.3% higher at $28.34, ...
Moderna is preparing to test Health Secretary Robert F. Kennedy Jr.'s tougher vaccine policies with a combination flu-COVID shot. The question is whether it gets approved for both viruses. Why it ...
Moderna (MRNA) steps into Thursday’s analyst day with more pressure than momentum. The stock is down more than 40% this year and over 85% in three years. Revenue is expected to fall another 40% in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results